×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
YourCentralValley.com
SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on May 10, 2024, the Compensation...
13 hours ago
Opinion: Travere’s Filspari Could Lead IgA Nephropathy Market
BioSpace
With its first-in-class endothelin and angiotensin II receptor antagonist Filspari, Travere Therapeutics is providing a more efficacious...
3 days ago
Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates
Yahoo News UK
Travere Therapeutics (TVTX) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.72.
1 day ago
Travere cuts 20% of workforce, counting on Filspari's full nod
Fierce Pharma
Travere Therapeutics will reduce its workforce by 20%, with the job cuts focused on “non-field-based employees,” the company said on...
5 months ago
Travere Therapeutics Provides Corporate Update and 2024 Outlook
ADVFN
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that, based on preliminary and unaudited financial data, the Company expects net product sales...
1 day ago
FY2026 EPS Estimates for Travere Therapeutics, Inc. Lifted by Analyst (NASDAQ:TVTX)
Defense World
Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) – Wedbush lifted their FY2026 earnings per share (EPS) estimates for shares of...
4 days ago
Travere Therapeutics to Present at Upcoming Investor Conferences
KXAN Austin
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will...
1 week ago
Travere Therapeutics First Quarter 2024 Earnings: Misses Expectations
Simply Wall Street
Travere Therapeutics ( NASDAQ:TVTX ) First Quarter 2024 Results Key Financial Results Revenue: US$41.4m (up 34% from 1Q...
1 week ago
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the ...
PR Newswire
PRNewswire/ -- CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that the European Commission has granted conditional...
3 weeks ago
Travere drug for rare kidney condition recommended for EU approval
Reuters
Vifor Pharma and partner Travere Therapeutics on Friday won an endorsement for approval from the European Union's drug regulator for their...
2 months ago